An unusual FDA panel on antidepressant use during pregnancy elevated clinicians and researchers who are deeply skeptical of ...

The Food and Drug Administration is considering adding warning labels to antidepressants for women who are pregnant, despite ...

Members of an advisory panel have proposed adding warning labels to some medication about adverse maternal and fetal risks in ...

When the U.S. Food and Drug Administration (FDA) convened a public expert panel to review the use of selective serotonin ...

Experts on the panel shared many of the same views around SSRIs, arguing the risks of the drugs during pregnancy are greater ...

Members of an FDA expert panel discussed the risks and benefits of selective serotonin reuptake inhibitors, or SSRIs, for ...

Last Monday, an expert panel convened by the U.S. Food and Drug Administration (FDA) to discuss the use of selective ...

At a recent FDA panel on SSRIs in pregnancy, the chair suggested rising antidepressant use may be contributing to — not easing — the nation’s depression rates.

A Food and Drug Administration panel discussing the use of antidepressants during pregnancy Monday largely amounted to ...

The U.S. Food and Drug Administration is turning its attention to selective serotonin reuptake inhibitors, a class of antidepressant drugs long criticized by Health and Human Services ...

A House subcommittee will hold a hearing today covering safety lapses and improvements to be made to the organ donor system. In other news: the FDA's debate on antidepressant use during pregnancy; the ...